2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3353 Early, delayed, and no response to frontline azacitidine-venetoclax in newly diagnosed AML: Distinct predictors and outcomes

Kuo-Kai Chin, M.D., Ali Kamali, PhD2, Alexander Chan, MD3, Andriy Derkach, PhD4, Baher Krayem, MD5, Wenbin Xiao, MD, PhD6, Eytan M Stein I, MD7, Greg Goldgof, MD8, Xin Wang, MD, MSCE9
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Background: Azacitidine-venetoclax (AZA/VEN) is preferred for older or frail patients (pts) with newly diagnosed (ND) AML and increasingly used in younger pts. As AZA/VEN can be continued indefinitely, clinicians frequently face decisions about continuing therapy in pts who have not achieved a response. However, no established criteria exist to guide this decision. Whether delayed responders achieve equivalent outcomes to early responders is also poorly understood. We sought to identify predictors that distinguish early, delayed, and nonresponders and to characterize outcome differences across these groups.

Methods: We performed a real-world, single-institution retrospective study of pts with ND AML who received AZA/VEN spanning 2020-2025. We utilized the Hematologic Multimodal Analytics Platform (MSK-HeMAP), a large language model (LLM)-enabled pipeline that reconstructs longitudinal disease trajectories from electronic health record data. Abstracted variables included demographics, AML risk classification, treatment and response, measurable residual disease (MRD) by flow cytometry, and survival. LLM outputs were reviewed and corrected by board-certified hematologists and pathologists. Overall response was defined as CR/CRi/CRh/MLFS per ELN 2022 criteria. Event-free survival (EFS, failure to respond, relapse, or death) and overall survival (OS) were estimated by Kaplan-Meier.

Results: A total of 260 evaluable pts were identified; 21 treated pts were non-evaluable due to missing post treatment bone marrow assessment due to toxicity, clinical discretion, or institutional change. Median age was 73 years and 59% of pts were male. Median cycles received was 3 (IQR: 2-4, range 1-36). Of evaluable pts, 64% (n=166) responded after cycle 1 (C1, “early responders, “ER”), 13% (n=34) responded C2 or later (“delayed responders,” “DR”), and 23% (n=60) were never-responders (NR).

Comparing ER and DR, there were no differences in baseline demographics or AML risk classification, including age, marrow blasts, cytogenetic risk, ELN 2022, ELN 2024. Individual molecular mutations (most common: DNMT3A, TET2, RUNX1, ASXL1, SRSF2, TP53) or key cytogenetic changes (most common: complex karyotype [CK], del17p/abn17, del7/7q, trisomy8) were not significantly associated with ER vs DR except CK (ER 18% vs DR 38%, p=0.029).

The distribution of best response categories between ER and DR were similar (67% vs 56% CR, 17% vs 29% CRi, 13% vs 6% CRh, 3% vs 8% MLFS, p=0.08). However, 51% of ER achieved MRD negativity at any point (MRD-, n=83), compared to 18% of DR (n=6, p<0.001). Among the 89 pts that achieved MRD-, 74% did so by C1, 88% by C2, and 94% by C3. Looking at survival, 3-mo landmark analysis showed no OS difference between ER and DR (39 vs 28 mo, HR 1.0, 95% CI 0.62-1.8 p=0.88). EFS with 3-mo landmark significantly favored ER over DR (33 vs 12 mo, HR 1.9 95% CI 1.2-3.1, p=0.008). MRD- by 3-mo was associated with improved OS in a 3-mo landmark (median OS 53 vs 21 mo, HR 2.2 95% CI 1.4-3.4, p<0.001), though no differences were seen with MRD- early (C1) vs MRD- late (C2+; HR 1.1 95% CI 0.43-3.0, p=0.81; reference MRD- early). Transplant rates were similar between ER (40%, n=67) and DR (41%, n=14), as was median time to transplant (ER 4.0, DR 4.1 mo from C1D1).

Comparing DR and NR, DR pts received a median of 3.5 cycles (IQR 3-6.75) vs 2 (IQR 1-3) for NR. 85% of DR responded after C2, 12% C3. Baseline demographics or AML risk classification, including cytogenetic risk, ELN 2022, and ELN 2024, did not differ. No individual molecular mutations differed significantly. However, del7/7q (DR: n=5, 15%, NR: n=25, 42%, p=0.003), del17p/abn17 (DR: n=7, 21%, NR: n=23, 38%, p=0.047), and del5q (DR: n=8, 24%, NR: n=25, 42%, p=0.045) were associated with NR. <25% blast reduction after C1 was associated with NR 82.4% of the time (PPV); ≥25% was associated with DR 89.7% of the time (NPV). OS with 3-mo landmark significantly favored DR compared to NR (28 vs 7.8, HR 2.3, 95% CI 1.3-4.0, p=0.005).

Conclusion: Most pts with ND AML treated with AZA/VEN respond by C1; DR was uncommon (13%) and rare beyond C2. Compared to ER, DR is associated with inferior EFS, similar OS, and lower rate of MRD clearance. Chromosome 7, 17, and 5q abnormalities and failure to achieve 25% blast reduction after C1 predict NR over DR. Pts with limited early blast reduction and adverse cytogenetics are unlikely to achieve DR and warrant early consideration of alternative therapies.

Kuo-Kai Chin, M.D.: Seres Therapeutics - Research Funding; Syndax Pharmaceuticals - Research Funding; Servier Laboratories - Consultancy (Includes expert testimony); Syndax Pharmaceuticals - Consultancy (Includes expert testimony)